Further insight into prognostic factors in endometrial cancer: the new serum biomarker HE4

References

• Brennan DJ, Hackethal A, Metcalf AM, et al. Serum HE4 as a prognostic marker in endometrial cancer –a population based study. Gynecol Oncol. 2014;132(no 1):159–165.
   PubMed Web of Science ®Google Scholar
• Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patiens with stage-1 endometrial carcinoma: muilticentrerandomized trial.PORTEC study group. Post operative radiation therapy in endometrial carcinoma. Lancet. 2000;355(9213):1404–1411.
   PubMed Web of Science ®Google Scholar
• Papanikolaou A, Kalogiannidis I, Goutzioulis M, et al. Pelvic Lymphadenectomy as alternative to postoperative radiotherapy in high risk early stage endometrial cancer. Arch Gynecol Obstet. 2006;274(2):91–96.
   PubMedGoogle Scholar
• Smith-Bindman R, Weiss E, Feldstein V. Howthick is too thick?When endometrial thicknes should prompt biopsy in postmenopausal women without vaginal bleeding. Ultrasound Obstet Gynecol. 2004;24(5):558–565.
   PubMed Web of Science ®Google Scholar
• Li J, Dowdy S, Tipton T, et al. HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev Mol Diagn. 2009;9(6):555–566.
   PubMed Web of Science ®Google Scholar
• Uharcek P. Prognostic factors in endometrial carcinoma. J Obstet Gynaecol Res. 2008 Oct;34(5):776–783.
   PubMed Web of Science ®Google Scholar
• Hirai M, Hirono M, Oosaki T, et al. Prognostic factors relating to survival in uterine endometrioid carcinoma. Int J Gynaecol Obstet. 1999;66(2):155–162.
   PubMed Web of Science ®Google Scholar
• Guntupalli SR, Zighelboim I, Kizer NT, et al. Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancer. Gynecol Oncol. 2012;124(1):31–35.
   PubMed Web of Science ®Google Scholar
• Abeler VM, Kjørstad KE, Berle E. Carcinoma of the endometrium in Norway: a histopathological and prognostic survey of a total population. Int J Gynecol Cancer. 1992;2(1):9–22.
   PubMed Web of Science ®Google Scholar
• Fujimoto T, Nanjyo H, Fukuda J, et al. Endometrioid uterine cancer: histopathological risk factors of local and distant recurrence. Gynecol Oncol. 2009;112(2):342–347.
   PubMed Web of Science ®Google Scholar
• Goodwin JS, Samet JM, Key CR, et al. Stage at diagnosis of cancer varies with the age of the patient. J Am Geriatr Soc. 1986;34(1):20–26.
   PubMed Web of Science ®Google Scholar
• Dobrzycka B, Mackowiak-Matejczyk B, Kinalski M, et al. Pretreatment serum level of bFGF and VEGF and its clinical significance in endometrial carcinoma. Gynecol Oncol. 2013;128(3):454–460.
   PubMed Web of Science ®Google Scholar
• Dobrzycka B, Terlikowski S. Biomarkers as prognostic factors in endometrial cancer. Folia Histochem Cytobiol. 2010;48(3):319–322.
   PubMed Web of Science ®Google Scholar
• Angioli R, Miranda A, Aloisi A, et al. A critical review on HE4 performance in endometrial cancer: where are we now? Tumour Biol. 2014 Feb;35(2):881–887.
   PubMed Web of Science ®Google Scholar
• Angioli R, Plotti F, Capriglione S, et al. The role of novel biomarker HE4 in endometrial cancer: a case control prospective study. Tumour Biol. 2013 Feb;34(1):571–576.
   PubMed Web of Science ®Google Scholar
• Capriglione S, Plotti F, Miranda A, et al. Utility of tumor marker HE4 as prognostic factor in endometrial cancer: a single-center controlled study. Tumour Biol. 2015 Jun;36(6):4151–4156.
   PubMed Web of Science ®Google Scholar
• Boronow RC, Morrow CP, Creasman WT, et al. Surgical staging in endometrial cancer: clinical-pathological findings of a prospective study. Obstet Gynecol. 1984;63:825–832.
   PubMed Web of Science ®Google Scholar
• DiSaia PJ, Creasman WT, Boronow RC, et al. Risk factors and recurrent patterns in stage I endometrial cancer. Am J Obstet Gynecol. 1985;151:1009–1015.
   PubMed Web of Science ®Google Scholar
• Creasman WT, Morrow CP, Bundy BN, et al. Surgical pathological spread patterns of endometrial cancer. A gynecologic oncology group study. Cancer. 1987;60:2035–2041.
   PubMed Web of Science ®Google Scholar
• Morrow CP, Bundy BN, Kurman RJ, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium. A gynecologic oncology group study. Gynecol Oncol. 1991;40:55–65.
   PubMed Web of Science ®Google Scholar
• Wilson TO, Podratz KC, Gaffey TA, et al. Evaluation of unfavorable histological subtypes in endometrial adenocarcinoma. Am J Obstet Gynecol. 1990;162:418–423.
   PubMed Web of Science ®Google Scholar
• Zaino RJ, Kurman RJ, Diana KL, et al. The utility of the revised international federation of gynecology and obstetrics histological grading of endometrial adenocarcinoma using a defined nuclear grading system. A gynecologic oncology group study. Cancer. 1995;75:81–86.
   PubMed Web of Science ®Google Scholar
• Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15:10–17.
   PubMed Web of Science ®Google Scholar
• Ambros RA, Sherman ME, Zahn CM, et al. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol. 1995;26:1260–1267.
   PubMed Web of Science ®Google Scholar
• Wheeler DT, Bell KA, Kurman RJ, et al. Minimal uterine serous carcinoma: diagnosis and clinicopathological correlation. Am J Surg Pathol. 2000;24:797–806.
   PubMed Web of Science ®Google Scholar
• Lax SF, Kurman RJ. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analysis. Verh Dtsch Ges Path. 1997;81:228–232.
   PubMedGoogle Scholar
• Matias-Guiu X, Catasus L, Bussaglia E, et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol. 2001;32:569–577.
   PubMed Web of Science ®Google Scholar
• Caduff RF, Johnston CM, Svoboda-Newman SM, et al. Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma. Am J Pathol. 1996;148:1671–1678.
   PubMed Web of Science ®Google Scholar
• Catasus L, Machin P, Matias-Guiu X, et al. Microsatellite instability in endometrial carcinomas: clinicopathological correlations in a series of 42 cases. Hum Pathol. 1998;29:1160–1164.
   PubMed Web of Science ®Google Scholar
• Risinger JI, Hayes AK, Berchuck A, et al. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res. 1997;57:4736–4738.
   PubMed Web of Science ®Google Scholar
• Bussaglia E, Del Rio E, Matias-Guiu X, et al. PTEN mutations in endometrial carcinomas: a molecular and clinicopathological analysis of 38 cases. Hum Pathol. 2000;31:312–317.
   PubMed Web of Science ®Google Scholar
• Tashiro H, Isacson C, Levine R, et al. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol. 1997;150:177–185.
   PubMed Web of Science ®Google Scholar
• Tritz D, Pieretti M, Turner S, et al. Loss of heterozygosity in usual and special variant carcinomas of the endometrium. Hum Pathol. 1997;28:607–612.
   PubMed Web of Science ®Google Scholar
• Carcangiu M, Chambers JT. Uterine papillary serous carcinoma: a study of 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion and concomitant ovarian carcinoma. Gynecol Oncol. 1992;47:298–305.
   PubMed Web of Science ®Google Scholar
• Zaino RJ, Kurman RJ, Herbold D, et al. The significance of squamous differentiation in endometrial carcinoma. Cancer. 1991;68:2293–2302.
   PubMed Web of Science ®Google Scholar
• Abeler VM, Kjorstad KE. Endometrial adenocarcinoma with squamous differentiation. Cancer. 1992;69:488–495.
   PubMed Web of Science ®Google Scholar
• Christopherson WM, Alberhasky RC, Connelly PJ. Carcinoma of the endometrium: I. A clinicopathological study of clear cell carcinoma and secretory carcinoma. Cancer. 1982;49:1511–1523.
   PubMedGoogle Scholar
• Tobon H, Watkins GJ. Secretory adenocarcinoma of the endometrium. Int J Gynecol Pathol. 1985;4:328–335.
   PubMed Web of Science ®Google Scholar
• Hendrickson MR, Kempson RL. Ciliated carcinoma, a variant of endometrial adenocarcinoma: a report of 10 cases. Int J Gynecol Pathol. 1983;2:1–12.
   PubMed Web of Science ®Google Scholar
• Chen JL, Trost DC, Wilkinson EJ. Endometrial papillary adenocarcinomas: two clinicopathological types. Int J Gynecol Pathol. 1985;4:279–288.
   PubMed Web of Science ®Google Scholar
• Zaino RJ, Kurman RJ, Brunetto VL, et al. Villoglandular adenocarcinoma of the endometrium: a linicopathological study of 61 cases. A gynecologic oncology group study. Am J Surg Pathol. 1998;22:1379–1385.
   PubMed Web of Science ®Google Scholar
• Ross JC, Eifel PJ, Cox RS, et al. Primary mucinous adenocarcinoma of the endometrium: a clinicopathological and histochemical study. Am J Surg Pathol. 1983;7:715–729.
   PubMed Web of Science ®Google Scholar
• Hendrickson MR, Ross J, Eifel P, et al. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol. 1982;6:93–108.
   PubMed Web of Science ®Google Scholar
• Abeler VM, Kjorstad KE. Serous papillary carcinoma of the endometrium: a histopathological study of 22 cases. Gynecol Oncol. 1990;39:266–271.
   PubMed Web of Science ®Google Scholar
• Abeler VM, Vergote IB, Kjorstad KE, et al. Clear cell carcinoma of the endometrium. Prognosis and metastatic pattern. Cancer. 1996;78:1740–1747.
   PubMed Web of Science ®Google Scholar
• Aquino-Parsons C, Lim P, Wong F, et al. Papillary serous and clear cell carcinoma limited to endometrial curettings in FIGO stage 1a and 1b endometrial adenocarcinoma: treatment implications. Gynecol Oncol. 1998;71:83–86.
   PubMed Web of Science ®Google Scholar
• Silverberg SG. Problems in the differential diagnosis of endometrial hyperplasia and carcinoma. Mod Pathol. 2000;13:309–327.
   PubMed Web of Science ®Google Scholar
• International Federation of Gynecology and Obstetrics (FIGO): Announcements. FIGO stages: 1998 revision. Gynecol Oncol. 1999;35:125–127.
   Google Scholar
• Taylor RR, Zeller J, Lieberman RW, et al. An analysis of two versus three grades for endometrial carcinoma. Gynecol Oncol. 1999;74:3–6.
   PubMed Web of Science ®Google Scholar
• Lax SF, Kurman RJ, Pizer ES, et al. A binary architectural grading system for uterine endometrial endometrioid carcinoma has superior reproducibility compared with FIGO grading and identifies subsets of advanced-stage tumors with favorable and unfavorable prognosis. Am J Surg Pathol. 2000;24:1201–1208.
   PubMed Web of Science ®Google Scholar
• Zaino RJ, Kurman RJ, Diana KL, et al. Pathological models to predict outcome for women with endometrial adenocarcinoma: the importance of the distinction between surgical stage and clinical stage. A gynecologic oncology group study. Cancer. 1996;77:1115–1121.
   PubMed Web of Science ®Google Scholar
• Abeler VM, Kjorstad KE. Endometrial adenocarcinoma in Norway. A study of a total population. Cancer. 1991;67:3093–4003.
   PubMed Web of Science ®Google Scholar
• Gal D, Recio FO, Zamurovic D. The new international federation of gynecology and obstetrics surgical staging and survival rates in early endometrial carcinoma. Cancer. 1992;69:200–202.
   PubMed Web of Science ®Google Scholar
• Wolfson A, Sightler S, Markoe A, et al. The prognostic significance of surgical staging for carcinoma of the endometrium. Gynecol Oncol. 1992;45:142–146.
   PubMed Web of Science ®Google Scholar
• Kosary CL. FIGO stage, histology, histological grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-1987 SEER cases of cancer of the endometrium, cervix, ovary, vulva, and vagina. Sem Surg Oncol. 1994;10:31–46.
   PubMedGoogle Scholar
• Maneschi M, Maneschi F, Geraci P, et al. Surgical pathological staging of endometrial adenocarcinoma and results of treatment. Eur J Gynecol Oncol. 1992;45:142–146.
   Web of Science ®Google Scholar
• Kurman RJ, Norris HJ. Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well-differentiated carcinoma. Cancer. 1982;49:2547–2559.
   PubMed Web of Science ®Google Scholar
• Longacre T, Chung MH, Jensen DN, et al. Proposed criteria for the diagnosis of well-differentiated endometrial carcinoma. A diagnostic test for myoinvasion. Am J Surg Pathol. 1995;19:371–406.
   PubMed Web of Science ®Google Scholar
• Eifel P, Ross J, Hendrickson M, et al. Adenocarcinoma of the endometrium. Analysis of 262 cases with disease limited to the uterine corpus: treatment comparisons. Cancer. 1983;52:1026–1031.
   PubMed Web of Science ®Google Scholar
• Ambros RA, Kurman RJ. Identification of patients with stage I uterine endometrioid adenocarcinoma at high risk of recurrence by DNA ploidy, myometrial invasion, and vascular invasion. Gynecol Oncol. 1992;45:235–239.
   PubMed Web of Science ®Google Scholar
• Lee KR, Vacek PM, Belinson JL. Traditional and nontraditional histopathological predictors of recurrence in uterine endometrioid adenocarcinoma. Gynecol Oncol. 1994;54:10–18.
   PubMed Web of Science ®Google Scholar
• Hall B, Young RH, Nelson JH. The prognostic significance of adenomyosis in endometrial carcinoma. Gynecol Oncol. 1984;17:32–40.
   PubMed Web of Science ®Google Scholar
• Jacques SM, Lawrence WD. Endometrial adenocarcinoma with variable-level myometrial involvement limited to adenomyosis: a clinicopathological study of 23 cases. Gynecol Oncol. 1990;37:401–407.
   PubMed Web of Science ®Google Scholar
• Mittal KR, Barwick KW. Endometrial adenocarcinoma involving adenomyosis without true myometrial invasion is characterized by frequent preceding estrogen therapy, low histological grades,and excellent prognosis. Gynecol Oncol. 1993;49:197–201.
   PubMed Web of Science ®Google Scholar
• Koshiyama M, Suzuki A, Ozawa M, et al. Adenocarcinoma Necol Pathol. 2002;21:239–245.
   Google Scholar
• Longacre TA, Hendrickson MR. Diffusely infiltrative endometrial adenocarcinoma: an adenoma malignum pattern of myoinvasion. Am J Surg Pathol. 1999;23:69–78.
   PubMed Web of Science ®Google Scholar
• Mittal KR, Barwick KW. Diffusely infiltrating adenocarcinoma of the endometrium: a subtype with a poor prognosis. Am J Surg Pathol. 1988;12:754–758.
   PubMed Web of Science ®Google Scholar
• Murray SK, Young RH, Scully RE. Unusual epithelial and stromal changes in myoinvasive endometrioid adenocarcinoma: a study of their frequency, associated diagnostic problems and prognostic significance. Int J Gynecol Pathol. 2003;22:324–333.
   PubMed Web of Science ®Google Scholar
• Silva EG, Jenkins R. Serous carcinoma in endometrial polyps. Mod Pathol. 1990;3:120–128.
   PubMed Web of Science ®Google Scholar
• Fanning J, Tsukada Y, Piver MS. Intraoperative frozen section diagnosis of depth of myometrial invasion in endometrial adenocarcinoma. Gynecol Oncol. 1990;37:47–50.
   PubMed Web of Science ®Google Scholar
• Goff BA, Rice LW. Assessment of depth of myometrial invasion in endometrial adenocarcinoma. Gynecol Oncol. 1990;38:46–48.
   PubMed Web of Science ®Google Scholar
• Hanson MB, van Nagell JR, Powell DE. The prognostic significance of lymph-vascular space invasion in stage I endometrial cancer. Cancer. 1985;55:1753–1757.
   PubMed Web of Science ®Google Scholar
• Sivridis E, Buckley CH, Fox H. The prognostic significance of lymphatic vascular space invasion in endometrial adenocarcinoma. Br J Obstet Gynaecol. 1987;94:991–994.
   PubMedGoogle Scholar
• Gal D, Recio FO, Zamurovic D, et al. Lymphovascular space involvement: a prognostic indicator in endometrial adenocarcinoma. Gynecol Oncol. 1991;42:142–145.
   PubMed Web of Science ®Google Scholar
• Beckner ME, Mori T, Silverberg SG. Endometrial carcinoma: nontumorfactors in prognosis. Int J Gynecol Pathol. 1985;4:131–145.
   PubMed Web of Science ®Google Scholar
• Katu T, Silverberg SG, Tsukamoto N, et al. Association of endometrial epithelial metaplasias with endometrial carcinoma and hyperplasia in Japanese and American women. Int J Gynecol Pathol. 1993;12:297–300.
   PubMed Web of Science ®Google Scholar
• Fanning J, Alvarez P, Tsukada Y, et al. Prognostic significance of the extent of cervical involvement by endometrial cancer. Gynecol Oncol. 1991;40:46–47.
   PubMed Web of Science ®Google Scholar
• Eltabbakh G, Moore A. Survival of women with surgical stage II endometrial cancer. Gynecol Oncol. 1999;74:80–85.
   PubMed Web of Science ®Google Scholar
• Boronow RC. Surgical staging of endometrial cancer: evolution, evaluation, and responsible challenge. A personal perspective. Gynecol Oncol. 1997;66:179–189.
   PubMed Web of Science ®Google Scholar
• Tambouret R, Clement PB, Young RH. Endometrial endometrioid adenocarcinoma with a deceptive pattern of spread to the uterine cervix: a manifestation of stage IIB endometrial carcinoma liable to be misinterpreted as an independent carcinoma or a benign lesion. Am J Surg Pathol. 2003;27:1080–1088.
   PubMed Web of Science ®Google Scholar
• Castrillon DH, Lee KR, Nucci MR. Distinction between endometrial and endocervical adenocarcinoma: an immunohistochemical study. Int J Gynecol Pathol. 2002;21:4–10.
   PubMed Web of Science ®Google Scholar
• McCluggage WG, Sumathi VP, McBride HA, et al. A panel of immunohistochemical stains, including carcinoembryonic antigen,vimentin, and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas. Int J Gynecol Pathol. 2002;21:11–15.
   PubMed Web of Science ®Google Scholar
• Kadar N, Homesley HP, Malfetano JH. Positive peritoneal cytology is an adverse risk factor in endometrial carcinoma only if there is other evidence of extrauterine disease. Gynecol Oncol. 1992;46:145–149.
   PubMed Web of Science ®Google Scholar
• Turner DA, Gershenson DM, Atkinson N, et al. The prognostic significance of peritoneal cytology for stage I endometrial cancer. Obstet Gynecol. 1989;74:775–780.
   PubMed Web of Science ®Google Scholar
• Grimshaw R, Tupper W, Fraser R, et al. Prognostic value of peritoneal cytology in endometrial carcinoma. Gynecol Oncol. 1990;36:97–100.
   PubMed Web of Science ®Google Scholar
• Geisinger KK, Homesley HD, Morgan TM, et al. Endometrial adenocarcinoma. A multiparameter clinicopathological analysis including the DNA profile and the sex steroid hormone receptors. Cancer. 1986;58:1518–1525.
   PubMed Web of Science ®Google Scholar
• van der Putten H, Baak JPA, Koenders T, et al. Prognostic value of quantitative pathological features and DNA content in individual patients with stage I endometrial adenocarcinoma. Cancer. 1989;63:1378–1387.
   PubMed Web of Science ®Google Scholar
• Sorbe B, Risberg B, Frankendal B. DNA ploidy, morphometry, and nuclear grade as prognostic factors in endometrial carcinoma. Gynecol Oncol. 1990;38:22–27.
   PubMed Web of Science ®Google Scholar
• Stendahl U, Strang P, Wagenius G, et al. Prognostic significance of proliferation in endometrial adenocarcinomas: a multivariate analysis of clinical and flow cytometric variables. Int J Gynecol Pathol. 1991;10:271–284.
   PubMed Web of Science ®Google Scholar
• Bast RC Jr, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309:883–887.
   PubMed Web of Science ®Google Scholar
• Aggarwal P, Kehoe S. Serum tumour markers in gynaecological cancers. Maturitas. 2010;67:46–53.
   PubMed Web of Science ®Google Scholar
• Ruan YQ, Liang WG, Huang SH. Analysis of laparoscopy on endometriosis patients with high expression of CA125. Eur Rev Med Pharmacol Sci. 2015;19:1334–1337.
   PubMed Web of Science ®Google Scholar
• Kirchhoff C. Molecular characterization of epididymal proteins. Rev Reprod. 1998;3(2):86–95. Review.
   PubMedGoogle Scholar
• Tang QF, Zhou ZW, Ji HB, et al. Value of serum marker HE4 in pulmonary carcinoma diagnosis. Int J Clin Exp Med. 2015;8:19014–19021.
   PubMed Web of Science ®Google Scholar
• Chen Y, Ren YL, Li N, et al. Serum human epididymis protein 4 vs. carbohydrate antigen 125 and their combination for endometrial cancer diagnosis: a meta-analysis. Eur Rev Med Pharmacol Sci. 2016 May;20(10):1974–1985.
   PubMed Web of Science ®Google Scholar
• Bie Y, Zhang Z. Diagnostic value of serum HE4 in endometrial cancer: a meta-analysis. World J Surg Oncol. 2014 May 29;12(1):169. DOI:10.1186/1477-7819-12-169
   PubMed Web of Science ®Google Scholar
• Hu L, Du S, Guo W, et al. Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in endometrial cancer: a meta-analysis. Int J Gynecol Cancer. 2016 Feb;26(2):331–340.
   PubMed Web of Science ®Google Scholar
• Moore RG, Brown AK, Miller MC, et al. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol. 2008;110(2):196–201.
   PubMed Web of Science ®Google Scholar
• Angioli R, Capriglione S, Scaletta G, et al. The role of HE4 in endometrial cancer recurrence: how to choose the optimal follow-up program. Tumour Biol. 2016 Apr;37(4):4973–4978.
   PubMed Web of Science ®Google Scholar
• Bignotti E, Ragnoli M, Zanotti L, et al. Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patiens. Br J Cancer. 2011;104:1418–1425.
   PubMed Web of Science ®Google Scholar
• Brennan DJ, Hackethal A, Mann KP, et al. Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance. BMC Cancer. 2015 Feb 6;15:33.
   PubMed Web of Science ®Google Scholar
• Moore RG, Miller CM, Brown AK, et al. Utility of tumor marker HE4 to predict depth of myometrial invasion in endometrioid adenocarcinoma of the uterus. Int J Gynecol Cancer. 2011;21(7):1185–1190.
   PubMed Web of Science ®Google Scholar
• Kalogera E, Scholler N, Powless C, et al. Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer. Gynecol Oncol. 2012;124(2):270–275.
   PubMed Web of Science ®Google Scholar
• Mutz-Dehbalaie I, Egle D, Fessler S, et al. HE4 is an independent prognostic marker in endometrial cancer patients. Gynecol Oncol. 2012;126(2):186–191.
   PubMed Web of Science ®Google Scholar
• Zanotti L, Bignotti E, Calza S, et al. Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome. Clin Chem Lab Med. 2012;50(12):2189–2198.
   PubMed Web of Science ®Google Scholar
• Saarelainen SK, Peltonen N, Lehtimäki T, et al. Predictive value of serum human epididymis protein 4 and cancer antigen 125 concentrations in endometrial carcinoma. Am J Obstet Gynecol. 2013;209(2):142.el-6.
   PubMed Web of Science ®Google Scholar
• Omer B, Genc S, Takmaz O, et al. The diagnostic role of human epididymis protein 4 and serum amyloid-A in early-stage endometrial cancer patients. Tumor Biol. 2013 Oct;34(5):2645–2650.
   PubMed Web of Science ®Google Scholar
• Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006;19:847–853.
   PubMed Web of Science ®Google Scholar
• Bolstad N, Oijordsbakken M, Nustad K, et al. Human epididymis protein 4 reference limits and natural variation in a Nordic reference population. Tumour Biol. 2012;33:141–148.
   PubMed Web of Science ®Google Scholar
• Kobel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoSMed. 2008;5(12):e232.
   PubMed Web of Science ®Google Scholar
• Plotti F, Capriglione S, Terranova C, et al. Does HE4 have a role as biomarker in the recurrence of ovarian cancer? Tumour Biol. 2012;33(6):2117–2123.
   PubMed Web of Science ®Google Scholar
• Creasman WT. FIGO stage 1988 revision. GynecolOncol. 1989;35:125–127.
   Google Scholar
• Plebani M, HE4 Study Group. HE4 in gynecological cancers: report of a European investigators and experts meeting. Clin Chem Lab Med. 2012;50:2127–2136.
   PubMed Web of Science ®Google Scholar
• Talhouk A, McConechy MK, Leung S, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer. 2015 Jul 14;113(2):299–310. DOI:10.1038/bjc.2015.190
   PubMed Web of Science ®Google Scholar
• Angioli R, Capriglione S, Aloisi A, et al. Can HE4 predict platinum response during first-line chemotherapy in ovarian cancer? Tumour Biol. 2014 Jul;35(7):7009–7015.
   Web of Science ®Google Scholar
• Angioli R, Capriglione S, Aloisi A, et al. REM (risk of endometrial malignancy): a proposal for a new scoring system to evaluate risk of endometrial malignancy. Clin Cancer Res. 2013 Oct 15;19(20):5733–5739.
   PubMed Web of Science ®Google Scholar
• Angioli R, Plotti F, Capriglione S, et al. Preoperative local staging of endometrial cancer: the challenge of imaging techniques and serum biomarkers. Arch Gynecol Obstet. 2016 Aug 17.
   Web of Science ®Google Scholar
• Angioli R, Aloisi A, Capriglione S, et al. Numquam ponenda est pluralitas sine necessitate? Ultrasound Obstet Gynecol. 2014 Sep;44(3):372–373.
   PubMedGoogle Scholar